Oh yes, now I recall ISS........ But first, excerpts / background from a past Business Sale Transaction (press releases)... Shareholder Conference Call/Webcast re Sale Transaction of Bioniche Animal Health to Vetoquinol (March 13, 2014) "...it is in the best interests of the Company for shareholders to approve the proposed sale transaction to Vetoquinol," stated Dr. Michael Berendt, CEO of Bioniche Life Sciences Inc. (Yup, this proved a winner for Company and shareholders) AND, "The Company's global commercialization strategy for Urocidin is very much partnership-driven" (BUT, not the U.S. market...engine failure?). AND, "The Company will be looking for line extensions or therapeutic combinations that will further extend the value of the product and its underlying MCNA technology" (too busy looking for partners??). AND, "The Company will also be seeking out additional clinical stage or near-clinical stage therapeutic assets that can be brought into the business to broaden the human health portfolio" (that broad pipeline didn't happen but today PLI would probably prefer TST's CASH in the BANK right now anyways) -- https://www.telestatherapeutics.com/cms/phph4aXow.pdf -- And, then the follow-up confirmation from ISS (interesting abbreviation). "ISS recommends that Bioniche shareholders vote in favour of Animal Health sale transaction". Despite being "an independent proxy advisory firm...to pension funds, investment managers, mutual funds, and other institutional shareholders...I wonder what they got paid for this and their latest reco? -- https://www.telestatherapeutics.com/cms/phph4aXow.pdf -- All in support of... "The Company's primary goal is to develop and commercialize products that advance human health and increase shareholder value". And, if all fails, do a "cash value" deal and book a long cruise trip with people that are not aware of your reputation/past record.